This report presents the results of a study that dealt specifically with effective communication around the benefit and risk balance of vaccination people’s risk perceptions around vaccines and diseases, and approaches to enhancing communication about the safety and effectiveness of vaccines.
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This reporting protocol is for the 2024 data call for antimicrobial resistance (AMR) surveillance data, collected by the European Antimicrobial Resistance Surveillance Network (EARS-Net) for 2023.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This is an operational document for those undertaking trend analyses using regression models. It provides guidance so that experts can carry out a trend analysis independently and understand when extra statistical support is needed.
This protocol sets out measures for the follow-up and management of individuals exposed to infected animals and human cases of avian influenza, and for the public health management of possible and confirmed human cases.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
Sample size calculation is an essential step in ensuring that analysis of the data which are collected through urveillance systems can support the desired public health objective(s). The main aim of sample size calculations is to determine the sample size needed from the population under study to possibly detect a statistically significant result.
This document describes how to strengthen surveillance in hospital settings for the identification of severely affected patients infected with avian influenza virus in the EU/EEA.